Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2CNS 1Breast 1

Conditions

Colorectal Neoplasms 80Colonic Neoplasms 18Neoplasm Metastasis 17Rectal Neoplasms 14Neoplasms 13Stomach Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lung Neoplasms 4Gastrointestinal Neoplasms 4Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Brain Neoplasms 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Unresectable Metastatic Colorectal Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Melanoma × IFL protocol × Clear all
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡